Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 2Rhabdoid Tumor 1Recurrence 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1

Interventions

Temozolomide 264Radiotherapy 119Bevacizumab 105Magnetic Resonance Spectroscopy 59Radiation 47pembrolizumab 30Irinotecan 28Surgical Procedures, Operative 23Lomustine 21Specimen Handling 19Nivolumab 19Radiosurgery 18Carmustine 18Aminolevulinic Acid 16Erlotinib Hydrochloride 15Drug Therapy 15Blood Specimen Collection 14Radiotherapy, Intensity-Modulated 13O(6)-benzylguanine 13Chemotherapy, Adjuvant 13Carboplatin 13Filgrastim 11Cyclophosphamide 11sargramostim 10poly ICLC 10atezolizumab 10Thalidomide 10Etoposide 10Ipilimumab 9Everolimus 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Glioblastoma × gallium maltolate × Clear all
NCT07515924 2026-04-07

Oral Gallium Maltolate for Recurrent Glioblastoma

Medical College of Wisconsin

Phase EARLY_PHASE1 Not yet recruiting
8 enrolled
CNS

Glioblastoma

NCT04319276 2025-11-03

Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma

Medical College of Wisconsin

Phase 1 Active not recruiting
26 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡